Endometrial cancer expresses the Mullerian Inhibiting Substance (MIS) type II receptor and is growth inhibited by MIS

Elizabeth Renaud, Esther Oliva, Bo R. Rueda, David T. MacLaughlin, Patricia K. Donahoe
In: Journal of the American College of Surgeons · 2004 · vol. 199(3) , pp. 82–83 · doi:10.1016/j.jamcollsurg.2004.06.001 · W2048293521
Lab / animal OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-23 ⓘ

This study demonstrates that endometrial cancer expresses the Mullerian Inhibiting Substance (MIS) type II receptor and exhibits growth inhibition when treated with MIS.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Renaud, Elizabeth J. MD; Oliva, Esther MD; Rueda, Bo PhD; MacLaughlin, David PhD; Donahoe, Patricia MD Author Information

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-10-27T06:37:41.825712+00:00
License: CC0 · commercial use OK